Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients

Antzeko izenburuak

• Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients
  nork: Susan Dutton, et al.
  Argitaratua: (2022-04-01)
• Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation
  nork: Brook, MO, et al.
  Argitaratua: (2024)
• Feasibility, long‐term safety and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients
  nork: Harden, PN, et al.
  Argitaratua: (2020)
• Application of operational tolerance signatures are limited by variability and type of immunosuppression in renal transplant recipients: A cross-sectional study.
  nork: Bottomley, M, et al.
  Argitaratua: (2016)
• Dampened inflammatory signalling and myeloid-derived suppressor-like cell accumulation reduces circulating monocytic HLA-DR density and may associate with malignancy risk in long-term renal transplant recipients
  nork: Bottomley, MJ, et al.
  Argitaratua: (2022)